Oliver Ottmann MD, FRCPath

Prof. Ottmann has led the development of novel drugs and highly targeted approaches, including immunotherapies and molecularly directed agents. He has served as principal investigator on numerous national and international First in Human, Phase I, II, and III clinical studies of many novel agents. His clinical and research efforts have been focused on providing therapy for patients suffering from treatment-resistant or refractory leukemia, with a special emphasis on acute lymphoblastic leukemia and on interrogating the mechanisms of resistance to targeted therapy. He has over 250 peer-reviewed publications focused on hematology developmental therapeutics and has particular interests in the mentoring of physician-scientists working on developmental therapeutics, as well as in developing national and international collaborations across the bioscience spectrum.